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Idiopathic pulmonary fibrosis (IPF) is characterized by pro-
gressive pulmonary scarring, decline in lung function, and often
results in death within 3–5 five years after diagnosis. Fibroblast
growth factor (FGF) signaling has been implicated in the patho-
genesis of IPF; however, themechanism throughwhich FGF sig-
naling contributes to pulmonary fibrosis remains unclear. We
hypothesized that FGF receptor (FGFR) signaling in fibroblasts
is required for the fibrotic response to bleomycin. To test this,
mice with mesenchyme-specific tamoxifen-inducible inactiva-
tion of FGF receptors 1, 2, and 3 (Col12-CreER; TCKO mice)
were lineage labeled and administered intratracheal bleomycin.
Lungs were collected for histologic analysis, whole lung RNA
andprotein, anddissociated for flow cytometry andFACS. Bleo-
mycin-treated Col12-CreER; TCKO mice have decreased pul-
monary fibrosis, collagen production, and fewer -smooth
muscle actin-positive (SMA) myofibroblasts compared with
controls. Freshly isolated Col12-CreER; TCKO mesenchymal
cells from bleomycin-treated mice have decreased collagen
expression compared with wild type mesenchymal cells. Fur-
thermore, lineage labeled FGFR-deficient fibroblasts have
decreased enrichment in fibrotic areas and decreased prolifera-
tion. These data identify a cell autonomous requirement for
mesenchymal FGFR signaling in the development of pulmonary
fibrosis, and for the enrichment of the Col12-CreER-positive
(Col12) mesenchymal lineage in fibrotic tissue following
bleomycin exposure. We conclude that mesenchymal FGF sig-
naling is required for the development of pulmonary fibrosis,
and that therapeutic strategies aimed directly at mesenchymal
FGF signaling could be beneficial in the treatment of IPF.
Pulmonary fibrosis is characterized by progressive scarring
of the lung, with abnormal production of extracellular matrix
by activated fibroblasts, ormyofibroblasts (1). In idiopathic pul-
monary fibrosis (IPF),2 the cause of fibroblast activation and
matrix deposition is unknown, although it is suggested to be a
result of aberrant healing from an injury of unknown origin (2).
IPF affects50,000 patients annually in the United States, and
the median survival is 3–5 years after diagnosis (1). Recently
approved novel antifibrotic agents Nintedanib (Ofev) and Pir-
fenidone (Esbriet) decrease the rate of decline in lung function
and improve survival in IPF (3, 4); however, overall outcomes
remain poor.
Fibroblast growth factors (FGFs) are implicated in the patho-
genesis of pulmonary fibrosis. The receptor tyrosine kinase
activity of FGF receptors (FGFRs) is inhibited byNintedanib (5,
6), which decreases bleomycin-induced fibrosis in mice (7, 8).
Inhibition of FGF signaling using a soluble ectodomain of
FGFR2c decreased TGF-1 induced primary lung fibroblast
proliferation and differentiation in vitro, as well as bleomycin-
induced fibrosis in vivo (9). This ectodomain inhibits multiple
FGFs known to bind to the IIIc splice variant of FGFR2, includ-
ing FGFs 1, 2, 4, 6, 8, 9, 17, and 18 (10). A recent study demon-
strated altered FGFR1 and FGF1 expression in IPF lungs, and
suggested that FGF signaling is critical for fibroblast migration
in pulmonary fibrosis (11). Additionally, administration of a
specific inhibitor of FGFR1 (NP603) inhibits carbon tetrachlo-
ride-induced hepatic fibrosis in rats (12). Although these stud-
ies have demonstrated the importance of FGF signaling in the
pathogenesis of pulmonary fibrosis, the cellular mechanisms
involved remain elusive. In particular, it is not knownwhich cell
type(s) are critical targets for FGFs in the pathogenesis of pul-
monary fibrosis in vivo.
In primary human lung fibroblasts, administration of
TGF-1 induced FGF receptor expression (13) and FGF2
expression and secretion into culture media (14, 15). Primary
lung fibroblasts isolated from rats exposed to peplomycin, a
bleomycin-related compound, have increased FGF2 produc-
tion (16). TGF-1-induced ERK, JNK, and AP-1 phosphoryla-
tion (14, 15), fibroblast differentiation intomyofibroblasts, pro-
liferation (17), and FGF2 production (18) are inhibited by
FGF2-neutralizing antibodies, suggesting a cooperative mech-
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anismbetween FGF2 andTGF-1. These data suggest that FGF
signaling in fibroblasts is critical in the pathogenesis of pulmo-
nary fibrosis.
To test whether FGF signaling in lung mesenchyme and
fibroblasts is required for the pathogenesis of pulmonary fibro-
sis in vivo, we have generatedmice with amesenchyme-specific
inducible knock-out of FGF receptors 1, 2, and 3 using mice
with tamoxifen-inducible Cre recombinase driven by the pro-
moter for procollagen I2 (Col12-CreER) (19–21). Simulta-
neous deletion ofmultiple FGF receptors was performed due to
overlapping receptor specificity ofmany FGFs, including FGF1,
FGF2, and FGF9 (22), as well as simultaneous expression of
multiple FGFRs in lung mesenchyme in vivo.
In this report we demonstrate that the Col12 lineage is
enriched in fibrotic tissue following bleomycin treatment, and
that cell-autonomous FGFR signaling is required for this
lineage enrichment. Deletion of FGFRs in lung mesenchyme
decreases collagen expression and the development of pulmo-
nary fibrosis in response to bleomycin. Our data suggests that
inhibition of FGFR signaling pathways in fibroblasts slows the
enrichment of lungmesenchyme into injured areas, providing a
mechanistic rationale for the use of FGF inhibitors to slow the
progression of pulmonary fibrosis.
Results
Gene expression in lungmesenchyme and fibroblasts
Mesenchymal cells were genetically tagged with a mem-
brane-localized green fluorescent protein (GFP) by mating
Col12-CreERmicewithROSA26mTmGCre reportermice (23).
Tamoxifen treatment of Col12-CreER; ROSA26mTmG/ mice
from postnatal day 21 (P21) to P35 labels peribronchiolar
smooth muscle and fibroblasts, perivascular smooth muscle,
and interstitial fibroblasts (Fig. 1,A andB). Co-immunofluores-
cence for GFP and PDGFR reveals that interstitial fibroblasts
targeted by Col12-CreER are PDGFR (Fig. 1C). Col12
(GFP) mesenchymal cells also express periostin and
-smooth muscle actin (SMA) (Fig. 1, D and E), but not
s100a4 (not shown) and epithelial-specific proteins such as pro-
surfactant protein C (pro-SPC) (Fig. 1F). In response to bleo-
mycin, lungmesenchymal cells targeted byCol12-CreERwere
enriched in areas of fibrosis as early as 14 days post-bleomycin
treatment (Fig. 1, G and H). Col12 cells in areas of fibrosis
express SMA (Fig. 1I), although not all SMA cells in
fibrotic areas were GFP.
Col12 cells make up 3.97  0.54% (n  8) of all single
cells from Col12-CreER; ROSA26mTmG/ mice treated with
tamoxifen (Fig. 2,A–D), and 32%ofCD45, CD31, EpCAM(Lin-
negative) cells (Fig. 2G). Very few Col12 cells are found in
the Lin-positive population (Fig. 2F). GFP cells were collected
from tamoxifen-treated mouse lungs by cell sorting, and expres-
sionofmesenchymal-specific geneswasmeasuredusingquantita-
tive RT-PCR and normalized to GAPDH and whole lung expres-
sion. Col12 mesenchymal cells were highly enriched for
Col11, Col12, Acta2, Periostin, and PDGFR (Fig. 2H).
Fgfr1 is expressed in mesenchymal cells and fibroblasts (22).
In IPF, expression of FGFRs 1–3 is increased in myofibroblasts
(11). To determine the potential for redundant function of Fgfr2,
Fgfr3, and Fgfr4 in mesenchymal cells and fibroblasts, we mea-
sured Fgfr expression in freshly isolated (non-cultured) Col12
mesenchymal cells. Analysis of Fgfr expression showed that Fgfr1
Figure 1. Localization of the Col12-CreER lineage and enrichment in fibrotic areas post-bleomycin. Col12-CreER; ROSA26mTmG/mice were treated
with tamoxifen at P21 and lungs were collected for frozen sections and imagedwith direct fluorescencemicroscopy (A and B). Arrows indicate primary sites of
Col12 peribronchiolar, perivascular, and interstitial cells. Frozen sections were stained for PDGFR (C), Periosin (D), SMA (E), and pro-SPC (F), and micros-
copy was performed for co-localization with GFP. Tamoxifen-treated Col12-CreER; ROSA26mTmG/mice were given a single dose of intratracheal bleomycin,
and lungs were analyzed after 14 (G) and 21 days (H) for GFP fluorescence. Co-immunofluorescence for SMA and GFP (I) was performed on 21-day post-
bleomycin lung sections.
Fibroblast-specific FGFR signaling in pulmonary fibrosis
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is the predominant FGF receptor expressed in Col12 cells.
Fgfr2,Fgfr3, andFgfr4were expressed at16-, 2.15-, and 2.82-fold
lower levels than Fgfr1, respectively (Fig. 2I).
When Col12 mesenchymal cells were cultured on colla-
gen-coated dishes, Fgfr1 remained the most abundant FGFR,
however, expression of Fgfr2 and Fgfr3was significantly dimin-
ished by passage number 2, and there was little measurable
Fgfr4 expression (Fig. 2J). These data indicate that to com-
pletely inhibit FGF signaling in lung mesenchyme in vivo, dele-
tion of multiple FGFRs is necessary, as they are capable of com-
pensatory signaling if only Fgfr1 is deleted.
Generation ofmesenchyme-specific FGF receptor knock-out
mice
Given significant expression of multiple FGF receptors in
lung mesenchyme in vivo, we generated mesenchyme-specific
knock-out of Fgfrs 1, 2, and 3 using the Col12-CreER allele.
Col12-CreER mice were crossed with Fgfr1f/f; Fgfr2f/f; Fgfr3f/f
triple flox mice (Fgfr1/2/3 TFF). Successful generation of
Col12-CreER; Fgfr1/2/3 TFFmicewas confirmed by PCR (Fig.
3A). Treatment of Col12-CreER; Fgfr1/2/3 TFF mice with
tamoxifen from P21 to P35 generated triple conditional knock-
out mice (Col12-CreER; TCKO) with significant reduction in
Fgfr-1, -2, and -3 expression in freshly sorted Col12mesen-
chymal cells (Fig. 3B). Expression of Fgfr4 was unchanged in
Col12-CreER; TCKO mice (Fig. 3B). Baseline expression, as
expressed by Ct, of mesenchymal-specific genes such as
Col11, Col12, Col31, Fibronectin, Pdgfra,-smoothmuscle
actin (Acta2), Periostin (Postn), Lysyl oxidase (Lox), s100a4,
and connective tissue growth factor (Ctgf) were also unchanged
in freshly sortedCol12-CreER; TCKOmesenchyme compared
with controls (Fig. 3C). The predominant mesenchymal genes
Figure 2. Isolation and gene expression of Col12mesenchymal cells. Tamoxifen-treated Col12-CreER; ROSA26mTmG/mouse lungs were harvested,
enzymatically dissociated, and GFP cells were identified via flow cytometry. Single cells were identified using forward and side scatter (A and B), and GFP
cells were identified (D). Analysis of Cre-negative ROSA26mTmG/ mouse lungs was used to confirm gating (C). Dissociated lungs were stained with BV421-
conjugated antibodies against CD31, CD45, and EpCAM (Lin) (E), and abundance of GFP cells was measured in both Lin-positive (F) and Lin-negative (G)
populations. PE, phycoerythrin. Total RNA was purified from freshly sorted GFP cells and analyzed via quantitative RT-PCR for expression of Fgfr1, Col11,
Col12, Acta2, Periostin, Pdgfr, Fgfr2, Fgfr3, and Fgfr4 (H and I). GFP cells were cultured, and RNA was collected from passage number 2 cells for qRT-PCR
analysis of Fgfr1, Fgfr2, Fgfr3, and Fgfr4 (J). qRT-PCR datawere normalized toGapdh and expressed asCt. * indicates p 0.05 comparedwithwhole lung RNA.
Fibroblast-specific FGFR signaling in pulmonary fibrosis
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expressed in freshly sorted Col12 cells were Col11 and
Col31 (Fig. 3C).
To determine whether lung mesenchyme from Col12-
CreER; TCKO mice have deficient FGF signaling, sorted
GFP cells (Col12 lineage) from tamoxifen-treated
Col12-CreER; TCKO; ROSA26mTmG/ and Col12-CreER;
ROSA26mTmG/mice were cultured and administered recom-
binant FGF2 (2 nM) for 48 h. Col12-CreER; TCKOmesenchy-
mal cells have decreased expression of FGF-dependent genes
Etv4 and Spry2 at baseline and in response to FGF2 (Fig. 4, A
and B). Additionally, Etv4 expression was significantly de-
creased in whole lung RNA and in RNA from freshly sorted
GFP cells from bleomycin-treated Col12-CreER; TCKO;
ROSA26mTmG/mice comparedwith controls (Fig. 4,C andD).
Western blot analysis from whole-lung protein lysates demon-
strated decreased phosphorylation of ERK1/2 in bleomycin-
treated Col12-CreER; TCKO mice compared with controls
(Fig. 5, A and B). Additionally, co-immunofluorescence for phos-
phorylated ERK1/2 and GFP demonstrated decreased phosphor-
ylation of ERK1/2 overall and in GFP cells (Fig. 5, C–J)
in bleomycin-treated Col12-CreER; TCKO; ROSA26mTmG/
mice compared with Col12-CreER; ROSA26mTmG/ controls,
indicating decreased FGFR-dependent activation of p42/44
MAPK pathways. These data show that mesenchymal cells
from Col12-CreER; TCKO mice have deficient FGF-induced
signaling and gene expression.
Decreased bleomycin-induced pulmonary fibrosis in
mesenchyme-specific FGFR knock-outmice
To test whether deletion of FGF receptors in mesenchyme
alters the development of pulmonary fibrosis in response to
bleomycin, Col12-CreER; TCKO mice and Cre-negative
Fgfr1/2/3 TFF controls were treated with tamoxifen (to gener-
ate Col12-CreER; TCKO and control mice) and subsequently
administered a single dose of intratracheal bleomycin (1.2
units/kg). Col12-CreER; TCKO mice had attenuated weight
loss post-bleomycin (Fig. 6A) and improved survival (Fig. 6B).
Histologic analysis revealed significantly decreased bleomycin-
induced pulmonary fibrosis in Col12-CreER; TCKO mice
compared with triple flox/flox (TFF) controls 21 days after
bleomycin onH&E-stained sections (Fig. 6D), byAshcroft scor-
ing (Fig. 6C), and on Masson trichrome-stained sections
(Fig. 6F). Quantitative hydroxyproline measurements revealed
decreased collagen deposition in Col12-CreER; TCKO mice
21 days post-bleomycin (Fig. 6E). There was no difference in
histologic fibrosis or hydroxyproline content betweenCre-neg-
ative TFF controls and mice containing only Col12-CreER
(Cre controls) in response to bleomycin (not shown).
To test whether mesenchyme-specific deletion of FGFRs is
required for bleomycin-induced expansion of myofibroblasts,
lungs from Col12-CreER; TCKO and Col12-CreER control
mice treated with intratracheal bleomycin were enzymatically
Figure 3. Generation ofmesenchyme-specific Fgfr1/2/3 triple conditional knock-outmice. Successful generation of Fgfr1f/f; Fgfr2f/f; Fgfr3f/f (Fgfr1/2/3 TFF)
mice was confirmed by PCR (A). Tamoxifen-treated Col12-CreER; Fgfr1/2/3 TFF; ROSA26mTmG/ (to generate Col1a2-CreER; TCKO; ROSA26mTmG/) and Col12-
CreER; ROSA26mTmG/ control mouse lungs were harvested, dissociated, and GFP cells were collected via cell sorting. Total RNA was purified from freshly
sorted GFP cells and analyzed via quantitative RT-PCR for Fgfr1, Fgfr2, Fgfr3, and Fgfr4 (B), as well as Col11, Col12, Col31, Fibronectin, Pdgfr, Postn, Acta2,
Lox, s100a4, and Ctgf (C). Data were normalized to Gapdh and expressed as Ct. * indicates p 0.05.
Fibroblast-specific FGFR signaling in pulmonary fibrosis
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dissociated 14 days after bleomycin, fixed, permeabilized,
stained with A647-conjugated antibodies against SMA, and
analyzed via flow cytometry. Compared with controls, Col12-
CreER; TCKO mice had fewer bleomycin-induced SMA
cells (Fig. 6G), indicating decreased numbers of myofibroblasts
in mice lacking mesenchymal Fgfrs-1, -2, and -3.
To determinewhether bleomycin-induced expression of col-
lagen and other pro-fibrotic genes were altered in Col12-
CreER; TCKO mice, whole lung mRNA was collected 21 days
after bleomycin treatment. Quantitative RT-PCR analysis
revealed decreased expression of collagen genes Col11 and
Col31 inCol12-CreER; TCKOmice comparedwithTFF con-
trols (Fig. 7, A and B). No significant difference in Col12 was
measured between bleomycin-treated control andTCKOmice,
although control mice, but not TCKO mice, demonstrated a
significant increase in Col12 expression in response to bleo-
mycin compared with PBS treatment (Fig. 7C). Col12-CreER;
TCKO mice had decreased bleomycin-induced expression of
several pro-fibrotic genes compared with controls, including
Ctgf, Lox, and Serpine-1a (Pai1) (Fig. 7, D–F). There was no
significant difference in expression of Postn, IL-6, vimentin, or
fibronectin in bleomycin-treated Col12-CreER; TCKO mice
compared with Fgfr1/2/3 TFF controls (Fig. 7, G and H, and
data not shown).
Reduced collagen expression in fibroblasts lacking Fgfrs
We then tested whether there was cell-autonomous FGFR-
dependent gene expression in lung mesenchyme following
bleomycin treatment. Col12-CreER; TCKO; ROSA26mTmG/
and Col12-CreER; ROSA26mTmG/ mice were administered
intratracheal bleomycin, and lungs were dissociated for cell
sorting 21 days post-bleomycin.GFP cells were sorted directly
into RNA lysis buffer, and analyzed by qRT-PCR. Freshly sorted
GFP cells from bleomycin-treated Col12-CreER; TCKO;
ROSA26mTmG/mice have decreased Col1a1 expression com-
pared with Col12-CreER; ROSA26mTmG/ controls (Fig. 8A),
but unchanged Col31, Col12, and Ctgf expression (Fig. 8,
B–D). GFPTCKO cells had decreasedCol31 expression fol-
lowing PBS treatment (Fig. 8B), and no significant change in
Lox and Pai1 expression (Fig. 8, E and F). GFP cells from
control mice, but not TCKO mice, demonstrated a significant
increase in Lox and Pai1 expression in response to bleomycin
compared with PBS treatment (Fig. 8, E and F). Additionally,
GFP cells from Col12-CreER; TCKO; ROSA26mTmG/mice
had significantly decreased bleomycin-induced Postn expres-
sion (Fig. 8G), and an attenuated reduction in Pdgfra in
response to bleomycin (Fig. 8H).
Freshly sorted GFP cells from Col12-CreER; TCKO;
ROSA26mTmG/ and Col12-CreER; ROSA26mTmG/ mice
were also cultured, serum-starved, and treated with 2 ng/ml of
TGF-1 for 48 h. GFP TCKO mesenchymal cells show
reduced Col11 expression compared with controls in re-
sponse to TGF-1 (Fig. 9A), but unchanged phosphorylation of
Smad2 (Fig. 9, B and C).
Mesenchyme-specific FGFR KOmice demonstrate decreased
enrichment of the Col12 lineage in fibrotic areas
We observed fewer GFP cells in bleomycin-treated
Col12-CreER; TCKO; ROSA26mTmG/ lungs, as seen in Fig. 5,
G–J, and hypothesized that the mechanism by which Col12-
CreER; TCKOmice have decreased fibrosis and myofibroblasts
after bleomycin injury is through impaired lineage expansion of
Col12 mesenchyme into areas of fibrosis. To test this,
Col12-CreER; TCKO; ROSA26mTmG/ and Col12-CreER;
ROSA26mTmG/ control mice were provided a 4-week washout
period post-tamoxifen, and administered intratracheal PBS or
bleomycin. The Col12 lineage was initially evaluated using
GFP immunofluorescence and co-localization with SMA 21
days post-bleomycin (Fig. 10, A–H). In bleomycin-treated
Col12-CreER; TCKO; ROSA26mTmG/mice, there were fewer
GFP cells in fibrotic areas, and fewer SMA cells through-
out the lungs compared with controls (Fig. 10, A–E, also see
Figs. 5, C–J, and 6G). To better determine SMA expression
in GFP TCKO mesenchymal cells, dissociated lungs from
bleomycin-treatedCol12-CreER; TCKO; ROSA26mTmG/ and
Col12-CreER; ROSA26mTmG/mice were stained with A647-
conjugated anti-SMA antibodies and analyzed by flow cytom-
etry. PBS-treated TCKO mice had unaltered abundance of
SMA cells in both GFP and GFP populations (Fig. 10, I
and J). Following bleomycin treatment, there were fewer
SMA, GFP cells in TCKO mice but unchanged SMA,
GFP cells in TCKO lungs compared with controls (Fig. 10, I
and J), suggesting an indirect effect of FGFR signaling onSMA
expression following bleomycin.
To quantify the abundance of GFP-labeled mesenchymal
cells in Col12-CreER; TCKO; ROSA26mTmG/ mouse lungs
Figure 4. Decreased downstream FGFR signaling in Col1a2-CreER; TCKO
mesenchymal cells. Col12-CreER; TCKO; ROSA26mTmG/ and Col12-CreER;
ROSA26mTmG/ mouse lungs were harvested, dissociated, and GFP cells
were collected via FACS and cultured for 2 passages. Cultured mesenchymal
cells were treated with recombinant FGF2 (2 nM) for 48 h and total RNA was
collected forquantitativeRT-PCRanalysis of andSpry2 (A) andEtv4 (B).Col1a2-
CreER; TCKO; ROSA26mTmG/ and Col12-CreER; ROSA26mTmG/ mice were
treatedwith intratracheal bleomycin, RNAwas collected fromwhole lungs (C)
or GFP cells isolated via FACS (D), and analyzed by qRT-PCR for Etv4 expres-
sion. Data were normalized to Gapdh and expressed as fold-change from
untreated control. * indicates p 0.05; ** indicates p 0.005; **** indicates
p 0.0001.
Fibroblast-specific FGFR signaling in pulmonary fibrosis
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compared with controls, GFP immunohistochemistry in areas
with similar amounts of fibrosis were compared. The Col12
lineage had decreased enrichment in areas of fibrosis following
bleomycin in TCKO mice (Fig. 11, A–C). Additionally, the
overall abundance of GFP cells, as a percentage of total lung
single cells detected using flow cytometry, was decreased in
TCKO mice compared with controls (Fig. 11D). The overall
abundance of GFP cells did not significantly increase follow-
ing bleomycin compared with PBS controls (not shown), con-
sistentwith prior reports (24).We then assessed proliferation in
response to bleomycin in TCKO mice by EdU labeling prior
to lung collection, enzymatic dissociation, and cell sorting.
Col12-CreER; TCKOmice have decreased numbers of EdU
cells within the overall single cell population and in the Lin-neg
mesenchymal population (Fig. 11, E and F), demonstrating
decreased proliferation in mesenchyme after bleomycin-
induced injury. We then measured growth in cultures of
Lin-neg, GFP cells isolated from Col12-CreER; TCKO;
ROSA26mTmG/ and control Col12-CreER; ROSA26mTmG/
mice 21 days after bleomycin. Compared with controls,
Col12-CreER; TCKO; ROSA26mTmG/ mesenchymal cells
demonstrate decreased growth over a 9-day period (Fig. 11G).
This demonstrates that FGFR signaling is required for prolifer-
ation and expansion of a pre-existing mesenchymal population
that contributes to bleomycin-induced pulmonary fibrosis.
Discussion
In this report, we demonstrate that FGFRs-1, -2, and -3 in
Col12 lung mesenchyme and fibroblasts are required for
bleomycin-induced pulmonary fibrosis and collagen produc-
Figure 5. Decreased ERK1/2 phosphorylation in Col1a2-CreER; TCKOmice. Col12-CreER; TCKO and control Fgfr1/2/3 TFFmice were administered a single
dose of intratracheal bleomycin (1.2 units/kg) or PBS. Total protein was isolated fromwhole lungs 21 days post-bleomycin, and analyzed byWestern blotting
for phosphorylated ERK1/2, total ERK1/2, and tubulin (A). Densitometric analysis was performed on n 3–4 replicates, and pERK1/2:total ERK1/2 ratios were
normalized to tubulin andexpressedas fold-change fromPBS-treated Fgfr1/2/3 TFF controlmice (B). * indicatesp0.05.C–J, lungs from21daypost-bleomycin
Col12-CreER; TCKO; ROSA26mTmG/ andCol12-CreER; ROSA26mTmG/micewere inflation-fixedwith 4%PFA (20 cmofH2Opressure), and frozen sectionswere
stained for phosphorylated ERK1/2. C and G, confocal images were obtained at 	40 magnification for GFP (green), ERK1/2 (red), and DAPI (blue). Higher
magnifications of areas indicated by dotted lines are shown for control (D–F) and TCKO (H–J) mice. Arrows indicate phospho-ERK1/2 positive cells. ns, not
significant.
Fibroblast-specific FGFR signaling in pulmonary fibrosis
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tion. Furthermore, we showed that FGFR signaling is required
for bleomycin-induced collagen expression in freshly isolated
fibroblasts. Additionally, intact FGFR signaling in lung mesen-
chyme is required for lineage-specific expansion of fibrotic tis-
sue in response to bleomycin.
FGF signaling has been implicated in the pathogenesis of
pulmonary fibrosis, as non-selective inhibition of receptor tyro-
sine kinases (7) and nonspecific inhibition of FGF receptors (9,
25) decrease bleomycin-induced pulmonary fibrosis in rodents.
FGFR signaling (in addition to VEGFR and PDGFR) is inhibited
byNintedanib, which decreases the rate of decline in lung func-
tion in IPF patients (3, 4). The mechanism by which inhibition
of multiple receptor tyrosine kinases decreases the progression
of pulmonary fibrosis remains unclear. Nintedanib reduces
fibronectin and collagen expression, induces autophagy, and
inhibits TGF signaling in IPF lung fibroblasts (26). Our data
demonstrates that there is a cell-autonomous role for FGFR
signaling in pulmonary fibrosis that promotes expansion of
Figure 6. Decreased bleomycin-induced fibrosis in Col1a2-CreER; TCKO mice. Col12-CreER; TCKO and control Fgfr1/2/3 TFF mice were administered a
single dose of intratracheal bleomycin (1.2 units/kg) or PBS. Mice weremonitored for weight loss (A) and survival (B) over a 21-day period. * indicates p 0.05
via two-way analysis of variance. Survival was analyzed using Kaplan-Meier survival analysis, * indicates p  0.05. Mouse lungs were collected 21 days
post-bleomycin for Ashcroft fibrosis scoring (C), H&E staining (D), quantitative hydroxyproline analysis (E), andMasson’s trichrome staining (F). Tomeasure the
number ofSMAmyofibroblasts, bleomycin-treated Col12-CreER; TCKO and control Col12-CreERmouse lungswere collected after 14 days, enzymatically
dissociated, fixed, permeabilized, stained for SMA, and analyzed by flow cytometry (G). * indicates p 0.05; ** indicates p 0.005. ns, not significant.
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lung fibroblasts into injured areas within the lung. A recent
report by MacKenzie et al. (11) described increased migration
of fibroblasts in response to FGF1, further supporting our find-
ings that FGF signaling is required for fibroblast expansion
within fibrotic areas.
Our studies use bleomycin as a model agent to induce fibro-
sis. One percent of patients treated with bleomycin develop
pulmonary fibrosis (27). Inmice, bleomycin causes alveolar epi-
thelial injury, inflammation, and fibroblast proliferation and
differentiation into myofibroblasts. Although bleomycin does
not cause lesions characteristic for IPF (fibroblastic foci and
honeycombing) in the mouse lung, bleomycin remains a well
established and useful model to study underlying mechanisms
of alveolar epithelial cell injury and subsequent fibroblast acti-
vation and fibrosis (27, 28, 30, 31).
Col12-CreER mice have been used previously to inactivate
genes in lung mesenchyme that are important for the develop-
ment of pulmonary fibrosis, including Tert (32), smoothened
(33), TgfR1 (19),Notch1 (34), and CEBP (20). It is important
to note that this allele targets multiple mesenchymal popula-
tions, and it is difficult to assess which population within the
Col12 lineage directly contributes to fibrotic areas in the
lung. Furthermore,we have found that cultured lung fibroblasts
generated from enzymatically dissociated Col12-CreER;
ROSA26mTmG/ whole lungs, without enrichment for GFP
cells via cell sorting, results in a heterogeneous population of
cells, with only 50–60% of the cells being GFP (not shown).
Incorporating the ROSA26mT/mG Cre reporter allele with the
Col12-CreER allele allows for direct analysis of lineage labeled
and genetically manipulated mesenchymal cells both in vivo
and in vitro.
This study underscores the importance of studying fibro-
blasts in vivo, as we have found that Fgfr expression changes
significantly once lung fibroblasts are placed in culture, even
after a single passage.We demonstrate significant expression of
all Fgfrs in freshly isolated lung mesenchyme; however, only
Fgfr1 is expressed when isolated fibroblasts are cultured. Low
levels of Fgfr3 and Fgfr4 expression in cultured lung fibroblasts
has previously been reported (35). FGFRs 1–4 were also found
to be expressed in myofibroblasts of fibroblastic foci in human
IPF lung biopsies (11). The mechanism(s) responsible for this
change in Fgfr expression is not known; however, altered cellu-
Figure 7. Decreased pro-fibrotic gene expression in Col1a2-CreER; TCKOmice after bleomycin treatment. Col12-CreER; TCKO and control Fgfr1/2/3 TFF
micewere administered a single dose of intratracheal bleomycin (1.2 units/kg) or PBS andmouse lungswere collected 21 days post-bleomycin for whole lung
RNA. Quantitative RT-PCR was performed for Col11 (A), Col31 (B), Col12 (C), Ctgf (D), Lox (E), Pai1 (F), Postn (G), and IL-6 (H). Data were normalized to Gapdh
and expressed as fold-change from PBS-treated Fgfr1/2/3 TFF controls. * indicates p 0.05; ** indicates p 0.005. ns, not significant.
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lar phenotypes and gene expression as a result of culture con-
ditions, including substrate stiffness and coating of culture
dishes have been well described (36).
Simultaneous deletion of multiple FGF receptors was per-
formed due to 1) overlapping receptor specificity ofmany FGFs
to FGFRs 1–3, including FGF1, FGF2, and FGF9 (22), and 2)
simultaneous expression of multiple Fgfrs in lung mesenchyme
in vivo (Fig. 2). Although mesenchymal cells with deletion of
FGFRs 1–3 demonstrate a functional deficiency of FGF signal-
ing, it remains possible that FGFR4 could further contribute to
lung fibroblast pathophysiology. Targeting Fgfr4 in lung mes-
enchyme and fibroblasts is an area of future study. Additionally,
the individual roles of FGFR1, FGFR2, and FGFR3 in lung mes-
enchyme following injury and in the development of pulmo-
nary fibrosis is not known, and future studies will be needed to
determine the relative contribution of individual FGFRs. Mice
expressing a soluble dominant-negative FGFR2 in late gesta-
tion, but not postnatally, causes airspace enlargement and
emphysema (37). FGFR3 may represent a significant FGFR in
adult lung pathophysiology. FGFR3 and FGFR4 have been
shown to be critical for early postnatal alveologenesis (35, 38),
and mice with combined deficiencies of Fgfr3 and Fgfr4 have
excessive elastic fiber deposition; however, their importance in
lung injury and pulmonary fibrosis are not well described.
Recent reports have also implicated FGFR3 in the pathogenesis
of lung cancer (39–41).
Althoughmesenchyme-specific FGFR signaling is important
for bleomycin-induced pulmonary fibrosis, the endogenous
FGF ligand(s) that mediate this pathology remains unclear.
FGF1 and FGF2 are capable of activating most FGF receptors,
including FGFR1, the mesenchyme-specific FGFR2c spice var-
iant, and FGFR3 (10, 22). Inhibition of FGFR2c ligands by
expressing a soluble FGFR2c ectodomain (25) decreases bleo-
mycin-induced fibrosis, and whereas this implicates FGF sig-
naling in the pathogenesis of fibrosis, it does not point to a
single ligand, as FGFR2c interactswithmultiple ligands, includ-
Figure 8. Decreased collagen expression in purified Col1a2-CreER; TCKO lung mesenchymal cells. Col12-CreER; TCKO; ROSA26mTmG/ and control
Col12-CreER; ROSA26mTmG/micewere treatedwith a single dose of intratracheal bleomycin (1.2 units/kg) or PBS. A, lungswere harvested and dissociated 21
days post-bleomycin, and GFP cells were collected via cell sorting directly into RNA lysis buffer. RNA purified from GFP cells was analyzed by quantitative
RT-PCR for Col11 (A), Col31 (B), Col12 (C), Ctgf (D), Lox (E), Pai1 (F), Postn (G), and Pdgfra (H). Data were normalized to Gapdh and expressed as fold-change
from PBS-treated controls. * indicates p 0.05; ** indicates p 0.005; *** indicates p 0.001; **** indicates p 0.0001. ns, not significant.
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ing FGF1, FGF2, FGF8, FGF9, and FGF18 (10). We recently
reported that Fgf2 knock-out mice have preserved fibrosis in
response to bleomycin (42), which suggests that other FGF
ligands are either required for bleomycin-induced fibrosis or
compensate for the absence of FGF2. A combined knock-out of
FGF1 and FGF2 has decreased carbon tetrachloride-induced
hepatic fibrosis (43), but the response of these mice to intratra-
cheal bleomycin is not known. FGF1 is increased in IPF lungs,
and is capable of increasing fibroblast migration in vitro (11).
FGF9 and FGF18 are increased in IPF, stimulate fibroblast
migration, and decrease fibroblast apoptosis (44, 45). Inhibition
of endogenous FGFR2b ligands (FGF7 and FGF10) does not
alter bleomycin-induced pulmonary fibrosis (46), suggesting
that these ligands are not essential for fibrosis. As the FGF
ligand(s) critical for bleomycin-induced fibrosis remain
unclear, further examination of the critical FGFRs are likely to
provide insight to the ligands involved, as FGF-FGFR specificity
is well described (22). Furthermore, pharmacologic targeting of
FGFRs may be more efficacious than targeting specific FGF
ligands, particularly given overlap in ligand-receptor interac-
tions and as multiple FGF ligands are likely involved in fibrosis.
Furthermore, targeting FGFR tyrosine kinases may potentially
be done in a cell-type specific manner. Continued studies using
Col12-CreER to inactivate individual Fgfrs will determine
which receptor is most critical for bleomycin-induced pulmo-
nary fibrosis, and will allow for improved therapeutics targeted
against fibroblasts contributing to fibrotic diseases.
FGF signaling in other cell types may also contribute to the
developmentof fibrosis.Arecent report suggested thatendothelial
FGFR1 signaling is required for hepatic fibrosis (47), as endotheli-
al-specific deletion of FGFR1 lessened liver fibrosis in response to
bile duct ligation. The role of endothelium and angiogenesis, and
in particular endothelial-specific FGF signaling, in pulmonary
fibrosis is not well understood (48) and warrants further study.
We show that inactivation of FGFRs in mesenchymal cells
decreases collagen expression in response to bleomycin and
TGF-1. This appears to be a cell-autonomous effect, as colla-
gen expression is altered in isolated Cre-expressing mesenchy-
mal cells following bleomycin treatment. These data also sup-
port prior reports where FGF2 signaling is required for TGF-1
induced collagen expression in lung fibroblasts (14, 15, 17).
Other studies have demonstrated an inhibitory effect of FGFs
on pulmonary fibrosis and TGF-1-inducedmyofibroblast dif-
ferentiation (44, 45, 49–52); however, those studies use exoge-
nous or overexpressed FGF ligands and no study to date has
demonstrated an inhibitory role of endogenous FGF ligands on
pulmonary fibrosis in vivo.
Our data also suggests that deletion of FGF receptors leads to
a cell non-autonomous effect onmesenchymal cells that are not
targeted by Col12-CreER. Deletion of FGFRs in the Col12
lineage leads to alteration in the abundance of GFP-negative,
SMA cells as well as expression of Col31, Ctgf, Lox, and
Pai1 in whole lung, but not GFP (Col12 lineage) mesen-
chymal cells. Future studies will investigate the factor(s)
involved in this interaction, as well as the cell types involved. It
should be noted that our experiments inactivated FGFRs prior
to lung injury, and future studieswill also addresswhether inac-
tivation of FGFRs in the Col12 lineage post-bleomycin has
similar cell autonomous and non-autonomous effects. Addi-
tional studies are needed to determine the mechanistic role of
FGFRs in multiple phases of fibroblast activation following
injury and in response to pro-fibrotic growth factors such as
TGF-1, including migration, metabolism, differentiation into
myofibroblasts, and recovery from injury.
In summary, this study provides direct evidence that deletion
of FGFRs in lung mesenchyme in adult mice decreases pulmo-
nary fibrosis, reduces fibroblast-specific collagen expression,
and decreases fibroblast enrichment in fibrotic areas in
response to bleomycin. This study provides a mechanistic
rationale for the use of FGF inhibitors to slow the progression of
pulmonary fibrosis. Improved understanding of the contribu-
tions of FGF and other growth factor pathways to the develop-
ment of fibrosis remains important, and future studies are
needed to determine fibroblast-specific, FGFR-dependent
pathways amenable to therapeutic intervention for improved
therapy in IPF and other fibrotic diseases.
Experimental procedures
Animal care and use
Micewere housed in a pathogen-free barrier facility and han-
dled in accordancewith standard protocols, animalwelfare reg-
ulations, and the NIH guide for the Care and Use of Laboratory
Animals. All procedures complied with the standards for the
care and use of laboratory animals as stated in the Guide or the
Care and Use of Laboratory Animals (NIH publication No.
85-23, revised 1996), and all protocols were approved by the
Animal StudiesCommittee atWashingtonUniversity School of
Medicine and at the University of Chicago.
Figure 9. Decreased collagen expression in response to TGF-1 in cul-
tured Col12-CreER; TCKO lung mesenchymal cells. GFP cells from un-
injured Col12-CreER; TCKO; ROSA26mTmG/ and control Col12-CreER;
ROSA26mTmG/micewere collected by cell sorting andgrown in culture. After
2 passages, cells were serum-starved overnight and treated with TGF-1 (2
ng/ml). RNAwascollected fromcells48hafter treatment, andanalyzedbyquan-
titative RT-PCR for Col11 (A). Data were normalized toGapdh and expressed as
fold-change from PBS-treated controls. B and C, total protein, collected after 1 h
of treatment, was analyzed byWestern blot analysis for phosphorylated Smad2
and tubulin. Densitometric analysis was performed on n  6 replicates, and
pSmad2 was normalized to tubulin and expressed as fold-change from control
(C). * indicates p 0.05; ** indicates p 0.005. ns, not significant.
Fibroblast-specific FGFR signaling in pulmonary fibrosis
J. Biol. Chem. (2017) 292(25) 10364–10378 10373
 at W
ashington U









Experiments were carried out usingCol12-CreERmice (53)
mated to mice containing floxed alleles for FGF receptors 1, 2,
and 3 (Fgfr1f/f; Fgfr2f/f; Fgfr3f/f) (54, 55) referred to as TFF. To
maintain this line of mice, male Col12-CreER; Fgfr1f/f; Fgfr2f/f;
Fgfr3f/f mice were mated to female Fgfr1f/f; Fgfr2f/f; Fgfr3f/f;
ROSA26mTmG/mTmG mice. Cre-negative TFF littermates and
Cre mice without floxed Fgfr alleles were used as controls.
Mice containing the Cre reporter allele and the ROSA26mTmG
allele allow for identification of targeted fibroblasts after treat-
ment with tamoxifen. After treatment with tamoxifen, these
mice are referred to as triple conditional knock-out mice
(Col12-CreER; TCKO). All mice weremaintained in a C57BL/
6J;129X1 mixed background.
Bleomycin-induced lung fibrosis
Micewere fed tamoxifen chow for 14 days starting at 3 weeks
of age, and subsequently fed regular chow. Adult mice between
8 and 10 weeks of age were sedated, orally intubated, and
administered a single dose of intratracheal bleomycin (1.2
units/kg) (Sigma) in sterile phosphate-buffered saline (PBS) or
PBS alone. Mice were monitored daily and weight was mea-
sured twice weekly. Mice with
25% weight loss or significant
respiratory distress were humanely euthanized and treated as a
death. At various times after treatment, mice were eutha-
nized with an overdose of a mixture containing ketamine and
xylazine, and exsanguinated by cutting the abdominal aorta.
Lungs were then slowly perfused with 5 ml of PBS via the
right ventricle. The trachea was dissected and cannulated,
and lungs were fixed via intra-tracheal inflation with 10%
phosphate-buffered formalin at a pressure of 20 cm H2O for
10 min, followed by immersion in fresh fixative for 24 h at room
temperature. Samples were then dehydrated in ethanol and
xylene, embedded in paraffin, cut in 5-m sections, and stained
with hematoxylin and eosin (H&E) andMasson’s trichrome.
Figure 10. Altered SMA expression in Col1a2-CreER; TCKO mice following bleomycin treatment. Col12-CreER; TCKO; ROSA26mTmG/ and control
Col12-CreER; ROSA26mTmG/micewereadministereda singledoseof intratrachealbleomycin (1.2units/kg)orPBS. (A–H) Sections from lungs collected21days
post-bleomycin were stained for SMA and GFP. A and E, confocal images were obtained at	20 magnification for GFP (green), SMA (red), and DAPI (blue).
Higher magnifications of areas indicated by dotted lines are shown for control (B–D) and TCKO (F–H) mice. Arrows indicate SMA cells. I and J, lungs were
dissociated, fixed, permeabilized, stained with BV421-conjugated antibodies against CD45, CD31, and EpAM (Lin) as well as A647-conjugated anti-SMA
antibodies, andanalyzedby flowcytometry. Lin-negative cellswere analyzed for expressionofGFPandSMA, and thepercentageof Lin-negative cells that are
SMA, GFP- (I) and SMA, GFP (J) are shown. * indicates p 0.05. ns, not significant.
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Ashcroft scoringwas performed as described previously (29).
Briefly, all lobes were sectioned on a single slide, and 20 non-
overlapping trichrome-stained	10 fieldswere scored per sam-
ple, and the average score of all fields indicates the Ashcroft
score of a single sample. The scoring scalewas as follows: 0no
abnormalities, 1  slight thickening of alveolar membranes,
2  small areas of fibrosis (10%), 3  10–20% fibrotic area,
4  20–40% fibrotic area, 5  40–60% fibrosis, 6  60–80%
fibrosis, 7
80% fibrosis, and 8 complete fibrosis.
Whole slide scanning
Digital scanning of whole slides was performed using a
Nanozoomer 2.0HTdigital slide scanner (Hamamatsu, Bridge-
water, NJ), available through the Washington University Hope
Center Alafi Neuroimaging Lab (NIH Shared Instrumentation
Grant (S10 RR027552)), or using an Aperio ScanScope XT
through the University of Chicago Human Tissue Resource
Center.
Hydroxyproline assay
Left lung samples were transferred into glass tubes and
hydrolyzedwith 200l of 6 NHCl at 110 °C for 48 h. The hydro-
lyzed samples were evaporated to dryness to remove excess
HCl, reconstituted with 400 l of H2O, and filtered in 1.5-ml
centrifuge tubes equipped with a 0.45-m semipermeable
membrane filter. Samples were added to a 96-well microplate,
chloramine T solution was added and the plate incubated at
Figure11.DecreasedproliferationandenrichmentofCol12 lineage in fibrotic areas inbleomycin-treatedCol1a2-CreER; TCKOmice.Col12-CreER;
TCKO; ROSA26mTmG/ and control Col12-CreER; ROSA26mTmG/micewere administered a single dose of intratracheal bleomycin (1.2 units/kg) and lungswere
collected 21 days post-bleomycin. Immunohistochemistry for GFP was performed (A and B) and the percentage of total fibrotic areas that were GFP was
analyzed using ImageJ (C). Whole lungs were dissociated and the percentage of total live single cells that were GFP following bleomycin treatment were
analyzed by flow cytometry (D). Proliferation was measured by injecting mice with EdU (50 mg/kg i.p.) prior to collection, and dissociated lungs were stained
for CD45, CD31, and EpCam (Lin), fixed, permeabilized, and then stained for EdU incorporation. Stained cells were measured by flow cytometry, and EdU
incorporation within all single cells (D) or Lin-negative cells (E) was analyzed. GFP cells from bleomycin-treated Col12-CreER; TCKO; ROSA26mTmG/ and
control Col12-CreER; ROSA26mTmG/mice were sorted into 96-well plates (2,000 cells/well) and cultured for 48 h, 5 days, 7 days, and 9 days prior to measure-
ment of total cellular DNA using a CyQuant assay (F). * indicates p 0.05; ** indicates p 0.005. ns, not significant.
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room temperature for 20 min. 100 l of Erlich’s reagent was
added to each well and the plate was incubated at 65 °C for 18
min. This method gives an orange-red color that is linear up to
6 g of hydroxyproline. A550 nm was obtained, and compared
with a hydroxyproline standard curve.
Immunohistochemistry and immunofluorescence
Five-m sections were prepared from paraffin-embedded
tissues, and deparaffinizedwith xylene. Endogenous peroxidase
was inhibited by incubation with 3% H2O2 in methanol, and
sections were then re-hydrated. Antigen retrieval was per-
formed using a pressure cooker and citrate buffer (pH 6.0).
Samples were incubated in PBS, and blocked in PBS  0.2%
Triton X-100 0.1% BSA 5% serum. Primary antibodies for
GFP (GFP-1010, Aves Inc, Tigard, OR), SMA (M0851, Dako
North America, Carpinteria, CA), PDGFRa (sc-338, Santa Cruz
Biotechnology, Dallas, TX), pro-SPC (ab90716, Abcam, Cam-
bridge, UK), s100a4 (ab27957, Abcam), and periostin (ab14041,
Abcam) were added to blocking buffer and slides were incu-
bated overnight at 4 °C. Slides were washed with PBS, and for
immunohistochemistry studies a biotin-conjugated secondary
antibody was added, followed by streptavidin-HRP. Colorimet-
ric reaction was performed using DAB staining (Vector Labs,
Burlingame, CA), and sectionswere counterstainedwith hema-
toxylin. Immunofluorescent imaging was performed using a
Zeiss Apotome or aMarianas Tokogawa spinning disk confocal
microscope, and image processing was performed using Zeiss
Axioplan and ImageJ (NIH, Bethesda, MD).
Quantification of GFP immunohistochemistry
Paraffin sections from PBS- and bleomycin-treated mice
were deparaffinized and stained with an anti-GFP antibody and
colorimetric reaction was performed using DAB staining.
10–15 non-overlapping 	10 fields containing areas of tissue
fibrosis were analyzed using ImageJ software to determine the
percentage of total fibrotic area that was stained for GFP.
RNA isolation and quantitative real-time PCR
RNA was isolated from whole lungs or whole left lungs via
homogenization in TRIzol, and subsequent purification using
RNeasy spin columns (74104, Qiagen, Valencia, CA), with on-
column DNA digest, per the manufacturer’s instructions. RNA
concentration was determined utilizing a Nanodrop spectro-
photometer. cDNAwasmade using theBio-Rad iScript Reverse
Transcription Supermix for RT-qPCR kit (170-8841, Bio-Rad).
Quantitative RT-PCR was performed on an Applied Biosys-
tems StepOne thermocycler using ABI TaqMan Fast
Advaned Master Mix (number 4444557, Applied Biosys-
tems, Foster City, CA) and TaqMan gene expression assays.
All samples were normalized to Gapdh and then scaled rel-
ative to controls using the standard Ct method. Data are
reported as Ct or fold-change relative to wild type PBS-
treated mice.
Protein extraction andWestern blotting
Protein was extracted fromwhole left lung or cultured fibro-
blasts via homogenization in RIPA buffer with freshly added 2%
Protease Inhibitor Mixture (P8340, Sigma) and Phosphatase
Inhibitor Mixture I and II (P2850 and P5726, Sigma). Protein
concentration was determined utilizing a Pierce BCA assay kit
(23225, Thermo Scientific, Rockford, IL). Total protein (50–
100g) was separated on 4–12%polyacrylamide gels (Bio-Rad)
and transferred to PVDFmembranes using a Trans-Blot Turbo
transfer system (Bio-Rad). Membranes were blocked for 1 h at
room temperature with gentle shaking in TBST (50 mM Tris,
pH 7.4, 150 mM NaCl, 0.1% Tween 20) containing 5% nonfat
milk or 5% BSA, and then probed with primary antibodies
against phospho-ERK1/2 (number 4376, Cell Signaling Tech-
nology, Danvers, MA), ERK1/2 (Cell Signaling number 9102),
tubulin (Abcam number ab6046), and phospho-Smad2 (Cell
Signaling number 3101) overnight at 4 °C. After three rinses in
TBST,membranes were incubated for 1 h at room temperature
in horseradish peroxidase-linked secondary antibodies in
TBST with 5% nonfat milk, rinsed again in TBST, and devel-
oped using SuperSignalWest Femto Substrate (34096, Thermo
Scientific). Protein bands were quantified using Image Lab
(Bio-Rad), normalized to tubulin, and scaled relative to control
samples set at a value of 1.
Flow cytometry and cell sorting
Micewere euthanizedwith an overdose of amixture contain-
ing ketamine and xylazine, and exsanguinated by cutting the
abdominal aorta. Lungs were then slowly perfused with 5 ml of
cold PBS via the right ventricle. The trachea was dissected and
cannulated, and lungs were inflated with DMEM digest media
containing LiberaseTM (Roche Diagnostics), hyaluronidase
(Sigma), elastase (Worthington Biochemical, Lakewood, NJ),
and DNase (Sigma). Inflated lungs were transferred to digest
media and placed on ice until all mice were dissected. Lungs
were then minced with razor blades and incubated in digest
medium at 37 °C for 30 min with agitation. Digest enzymes
were inactivated with DMEMwith 10% FBS, and samples were
filtered with a 100-m strainer. Red blood cells were then lysed
with ACK buffer (Thermo Scientific) and cells were resus-
pended in FACS buffer (PBS  3% FBS  1 mM EDTA). Cells
were stainedwith BV-421-conjugated antibodies against CD45,
CD31, and CD326 (EpCAM) (BioLegend, San Diego, CA).
GFP cells were sorted using a Sony Synergy (Washington
University) or FACSAria II (University of Chicago), using a
100-mdiameter nozzle. For culture, cells were sorted directly
into complete media containing 10% FBS. For RNA isolation,
between 50,000 and 100,000 cells were sorted directly into RLT
lysis buffer with -mercaptoethanol, and RNA was purified
using an RNeasy Plus Micro Kit (Qiagen).
For detection of SMAmyofibroblasts via flow cytometry,
dissociated cells were stained with BV-421-conjugated anti-
bodies against CD45, CD31, and CD326 (EpCAM), and subse-
quently fixed with 4% paraformaldehyde. Fixed cells were
washed with PBS 1% BSA 0.1% sodium azide and permea-
bilized using the BD cytofix/cytoperm kit (BD Biosciences).
Fixed cells were stained with A647-conjugated anti-SMA
antibodies (number NBP2–34522AF647, Novus Biologicals,
Littleton, CO), washed, and measured using a BD LSR II flow
cytometer. Data were analyzed using FlowJo software.
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Lung fibroblast isolation and culture
GFP-labeled cells were sorted directly into culture media,
and subsequently cultured on collagen-coated plates in DMEM
with 10% FBS, penicillin/streptomycin, fungizone, L-glutamine,
and HEPES. Cells were grown in a humidified incubator at
37 °C with 5% CO2. Media was replaced every other day, and
cultured fibroblasts were used for experiments between pas-
sages 2 and 5.
In vivo proliferation assay
Prior to collection, mice were given an intraperitoneal injec-
tion of EdU (50 mg/kg, Thermo Fisher). Mouse lungs were
enzymatically dissociated as described above, and cells were
stained with BV-421-conjugated antibodies against CD45,
CD31, and CD326 (EpCAM) (BioLegend). Cells were then
fixed, permeabilized, and stained for EdU using the Click-iT
EdU assay (Thermo Fisher) according to the manufacturer’s
protocol. Flow cytometry was performed using a BD LSR II
cytometer, and data analyzed using FlowJo.
In vitro proliferation assay
Mouse lungs were dissociated and stained with BV-421-con-
jugated antibodies against CD45, CD31, and CD326 (EpCAM)
(BioLegend) as described, dead cells were excluded using
7-aminoactinomycin staining, and 2000 GFP cells were
directly sorted into individual wells of 96-well collagen-coated
plates containing complete media using a FACSAria II sorter.
Cells were grown as described above. At specified times, plates
were washed with PBS and placed at80 °C. DNA content was
measured using a CyQuant assay per manufacturer protocol.
Statistical analysis
Significant differences in mean values were calculated using
paired Student’s t tests or one-way analysis of variance. Survival
analysis was performed using Kaplan-Meier analysis. A p value
of less than 0.05 was considered to be significant.
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